threshold, and 2) the health effects of the new technology with the health effects of those technologies which must be displaced to accommodate its additional costs. The performance of each is evaluated through a simulation exercise, which using shopping at the supermarket as an analogy to the health care system. An initial basket of goods represents the initial allocation and specifies the budget constraint. The task is to improve the contents of the basket by examining other things on the shelves and applying one of the decision rules. Performance is measured by: 1) how close each can get to the optimal basket (a MP solution), and 2) how quickly each improves the initial basket. We explore when each decision rule performs at its best and when one is likely to outperform the other. This includes: indivisibly of technologies and programmes, size of the budget relative to programme costs, the efficiency of exiting technologies; the type of information available to decision makers and whether they are able to learn from examining more products. This helps to identify where additional information (e.g., a better estimate of the threshold) might be most valuable.
Personalized medicine (PM) is notably typified by the development of companion diagnostic tests to guide optimal treatment selection. PM has thus the potential to dramatically improve patients' outcomes and optimise allocation of resources. However, very few attempts exist that transparently include diagnostic test performance such as Sensitivity (Se) and Specificity (Sp) into cost-effectiveness and budget impact models. This research proposes an analytical framework to unveil diagnostic added-value according to different diagnostic performance scenario. The framework is based on a decision tree and compares two hypothetical treatments N vs. C. N is a new treatment associated with a companion diagnostic test T. C is the current standard of care not associated with any test. T selects the likely responding patients based on the presence (Tϩ) or absence (TϪ) of a predictive sign of response to N (a distinctive biomarker for instance). We demonstrate that it is the prior prevalence of the sign within the target population coupled with the expected effectiveness differential between N and C in true positive patients and with the performance of the test (Se and Sp) that are the fundamental determinants of the potential value of a PM strategy. An extension of the model to the case of 2 competing PM strategies (and thus 2 competing tests) is shown. We conclude that companion diagnostic test performance is key to achieve the promises of PM. This analytical framework allows payers, HTA bodies and manufacturers to gauge the potential value and financial impact of a PM strategy at all stage of its development. Issues on discounting health effects have spurred debates on appropriate decision rules. Consensus is that empirically observed rates of time preference be incorporated in analysis. The latter, however, is known to suffer from cognitive limitations. The human nervous system perceives how long sensory events last and the latter impact on perceptual decision making which is the act of choosing from a set of alternatives on the basis of available sensory evidence; in our case the indifference balance between present and future consumption. Statistical tools for such purposes are however scarce and normality assumptions often fail to hold. We therefore derive a stochastic distribution by maximum entropy principle(MaxEnt). A MaxEnt distribution is one which best represents the current state of knowledge. Furthermore, MaxEnt distributions minimize the amount of prior information built into the distribution. Such distributions are usually sought by maximization of entropy constrained on what is known. In our case, we assume that the expected indifference amount at time t compared to an amount, y 0 , now is given by E(Y(t))ϭy 0 /w(t) where w(t) is a general time-inhomogeneous discount weight. With that constraint and the usual probability constraints, we derive a maximum entropy distribution for such a future amount. That is, we provide a closed-form distribution of the probability that an individual is indifferent between some quantity Y(t)ϭy at time t and a quantity Y(0)ϭy 0 now given E(Y(t))ϭy 0 /w(t).
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PRM174 THE NEED TO CONDUCT FUTURE RESEARCH ON THE BENEFIT OF THE PROSTATE SPECIFIC ANTIGEN SCREENING TEST USING THE VALUE OF INFORMATION FRAMEWORK
Reese ES, Mullins CD University of Maryland School of Pharmacy, Baltimore, MD, USA OBJECTIVES: Prostate cancer (PC) is the second most common cancer in men worldwide and the second leading cause of cancer deaths in men in the United States. Recently, the prostate specific antigen (PSA) test used to screen and diagnosis PC has been questioned due to concerns regarding clinical utility and its inability to accurately identify men with PC. This research aims to estimate the Value of Information (VoI) of the PSA screening research and to determine whether future PSA screening research should be focused on specific populations. METHODS: This research uses the Minimal Modeling Approach (MMA) in order to determine the expected value of information for PSA research. The population expected value of information (pEVI) for racial (African Americans and non-African Americans) and age (65-75 years, 76-85 years, Ͼ85 years) subgroups will be deter-mined. Investigators will model survival based on published randomized controlled trials of PSA screening and will use data from the Surveillance Epidemiology and End-Result (SEER)-Medicare dataset for both survival and costs. Investigators will structure analyses by modeling the net benefit of men who received a prostate specific antigen screening exam between 2000 and 2007. RESUTS: VoI is recognized for providing a framework for estimating the expected benefits of clinical research. Due to the controversy surrounding the PSA screening test, patients and clinicians are challenged when trying to make informed decisions regarding diagnosis and treatment of PC. CONCLUSIONS: This research seeks to determine where the greatest return on research investment would provide a more accurate evidence base for PSA screening for PC.
PRM175 IDENTIFICATION AND TRANSLATION OF CULTURALLY BOUND TERMS IN PATIENT REPORTED OUTCOME MEASURES
Simpson H, Two R, Verjee-Lorenz A, Clayson D PharmaQuest Ltd, Banbury, UK Patient reported outcome (PRO) measures typically undergo a precise and detailed translation process which involves the input of translators, investigators, project managers and developers in order to produce the most accurate and fluent translation possible. In order for the pooling of data from international clinical trials to be possible, it is important that translations of a PRO measure mean the same to all respondents, not just in terms of the phrasing, but also in terms of the intensity and nuance of the phrases used. It is often the case that terms used frequently in PRO measures will have a direct and literal translation into the target language. However, problems can occur when terms used in the source text are culturally bound -i.e., when the direct translation of a term has a different meaning than that of the source text, in terms of intensity or connotations, or is used in a different way. For example, the term 'frustrated' has a direct translation in most languages; however, this term has a stronger meaning in some countries and can refer to a mental health issue. Issues can also arise when there is no equivalent of the source term in the target language. We will discuss common terms, expressions and nuances that are frequently used in PRO measures and how their meaning can be different across varying languages and cultural backgrounds. We will examine how to preempt these issues and how to avoid the mistranslation of culturally bound terms, by discussing the importance of detailed concept elaboration documents, input from the instrument developer, and in-depth pilot testing and cognitive debriefing. By using these methods it is possible to accurately anticipate these potential issues and explore alternative ways of conveying the intended meaning.
PRM176 THE VALUE OF FURTHER RESEARCH: THE ADDED VALUE OF INDIVIDUAL-LEVEL DATA
Saramago P University of York, York, North Yorkshire, UK OBJECTIVES: Judgements based on average cost effectiveness estimates may disguise sources of heterogeneity that should be reflected in decision making. Making decisions considering between patient heterogeneity has been proved consistent with an efficient use of limited resources. Although individual level data (IPD) is often not available to inform decision models, these provide unbiased and more precise estimates, particularly in the presence of heterogeneity. This paper seeks to assess the added value of having access to IPD, compared to using aggregate data (AD) only, in appropriately performing subgroup value of information analysis. METHODS: This paper develops a framework that informs the understanding of the implications of considering IPD when assessing the value of additional research in the absence and in the presence of mutually exclusive population subgroups. RESULTS: The developed framework explores the capabilities of the available evidence (i.e. IPD and AD) in guiding and in quantifying the value of further research in the absence and presence of subgroups. Issues around the optimal number of subgroups and for which population subsets should further research be undertaken are discussed. These exercises are supported by a motivating example on the cost effectiveness of child accident prevention programmes. CONCLUSIONS: The use of IPD rather than AD estimates may influence not only the extent to which an appropriate understanding of existing heterogeneity is attained, but, more importantly, it may shape approval decisions for particular population subgroups and judgements of furtherresearch. OBJECTIVES: Biomarkers associated with treatment efficacy and safety can be used to develop pharmacogenomic tests. However, translation of the evidence into clinical practice is difficult due to barriers to development and the difficulty to demonstrate clinical and economic utility. Health technology assessment (HTA) methodology may be used to inform decisions at many points during the product lifecycle. We assessed the role of HTA in the development phase of pharmacogenomic tests in multiple myeloma. METHODS: Early-Stage hta was conducted separately for two clinical applications of biomarkers: 1) a safety-based companion diagnostic, and 2) a prognostic test. We reviewed the methods that were useful in answering the questions about the health benefits and costs of the intervention and comparators strategies in each scenario were reviewed. RESULTS: An evidence-based approach was applied for both scenarios. Using literature reviews and A492 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
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